Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ET

Company Participants

Lisa Conte - President & Chief Executive Officer

Carol Lizak - Chief Financial Officer

Ian Wendt - Chief Commercial Officer

Conference Call Participants

Operator

Good morning.

Before I turn the call over to management, I would like to remind you that management may make forward-looking statements relating to such matters as contained growth prospects for the company, uncertainties regarding market acceptance of products and the impact of competitive products and pricing, industry trends and product initiatives, including projects in the development stage which may not achieve scientific objectives or be stringent regulatory requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially than those contemplating in such forward-looking statements. These statements are based on currently available information and management's current assumptions, expectations and projections about future events. While management believes its assumptions, expectations and projections are reasonable in view of currently available information, your question not to place undue reliance on these forward-looking statements.

The company's actual results may differ materially from those discussed in today's -- during this webcast for a variety of reasons, including those described in forward-looking statements and Risk Factors sections of the company's Form 10-K for the year of 2022 which was filed, March 24, 2023 and its other filings with the SEC which are available on the Investor Relations section of Jaguar's website. Except as required by law, Jaguar undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information and future events or otherwise. Additionally, please note that the company supplements its condensed consolidated financial statements presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA. Jaguar believes that the disclosed items of those non-GAAP measures provide investors with additional information that reflects the basis upon which the company management assesses and operates the business. These non-GAAP financial measures should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for or superior to measures of financial performance and conformity with GAAP. Today's conference is being recorded.

At this time, it is now my pleasure to turn the conference over to Lisa Conte, Jaguar Health's Founder, President and Chief Executive Officer. Lisa, the floor is yours.

Lisa Conte

Thank you very much and welcome to all. As you just heard, my name is Lisa Conte and I'm the Founder, President and CEO of Jaguar Health and our wholly owned subsidiary in the United States Napo Pharmaceuticals. Sometimes we use Napo and Jaguar names interchangeably. I'm also a member of the Board of Napo Therapeutics, the corporation we established in 2021 in Milan, Italy which is focused on expanding access to Crofelemer in Europe, in particular for rare disorders.